Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 243-251

  Pussegoda, K ^a,b   Ross, C J ^a,b   Visscher, H ^a,b   Yazdanpanah, M ^a,b   Brooks, B ^c   Rassekh, S R ^b,c   Zada, Y F ^d   Dube M P ^d   Carleton, B C ^a,b,c   Hayden, M R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER C3; CATECHOL METHYLTRANSFERASE; CISPLATIN; DNA; GENTAMICIN; THIOPURINE METHYLTRANSFERASE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VINCRISTINE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; BRAIN RADIATION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOMA; CHEMOTHERAPY INDUCED HEARING LOSS; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GERM CELL TUMOR; GROUPS BY AGE; HEARING IMPAIRMENT; HEPATOBLASTOMA; HUMAN; INFANT; LIVER TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; OSTEOSARCOMA; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; RISK ASSESSMENT; SARCOMA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; CISPLATIN; CRANIOSPINAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VARIATION; GENOTYPE; HEARING LOSS; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHYLTRANSFERASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84880756433     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.80     Document Type: Article

References (53)

1. Perilongo, G. et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N. Engl. J. Med. 361, 1662-1670 (2009).
2. Kling, J. US FDA contemplates collection of pharmacogenomic data. Nat. Biotechnol. 21, 590 (2003).
3. Li, Y., Womer, R.B. & Silber, J.H. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 40, 2445-2451 (2004). (Pubitemid 39424959)
4. Brock, P.R., Bellman, S.C., Yeomans, E.C., Pinkerton, C.R. & Pritchard, J. Cisplatin ototoxicity in children: a practical grading system. Med. Pediatr. Oncol. 19, 295-300 (1991).
5. Blakley, B.W. & Myers, S.F. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol. Head. Neck Surg. 109, 385-391 (1993). (Pubitemid 23318944)
6. Ilveskoski, I. et al. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med. Pediatr. Oncol. 27, 26-31 (1996).
7. Skinner, R., Pearson, A.D., Amineddine, H.A., Mathias, D.B. & Craft, A.W. Ototoxicity of cisplatinum in children and adolescents. Br. J. Cancer 61, 927-931 (1990). (Pubitemid 20197008)
8. Montaguti, M., Brandolini, C., Ferri, G.G., Hatzopoulos, S., Prete, A. & Pession, A. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention]. Acta Otorhinolaryngol. Ital. 22, 14-18 (2002).
9. Ross, C.J. et al.; CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
10. Ekborn, A., Laurell, G., Andersson, A., Wallin, I., Eksborg, S. & Ehrsson, H. Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig. Hear. Res. 140, 38-44 (2000). (Pubitemid 30079633)
11. Lewis, M.J., DuBois, S.G., Fligor, B., Li, X., Goorin, A. & Grier, H.E. Ototoxicity in children treated for osteosarcoma. Pediatr. Blood Cancer 52, 387-391 (2009).
12. Knight, K.R., Kraemer, D.F. & Neuwelt, E.A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 23, 8588-8596 (2005). (Pubitemid 46211500)
13. Bertolini, P. et al. Platinum compound-related ototoxicity in children: longterm follow-up reveals continuous worsening of hearing loss. J. Pediatr. Hematol. Oncol. 26, 649-655 (2004). (Pubitemid 39350398)
14. Bokemeyer, C. et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 77, 1355-1362 (1998). (Pubitemid 28140629)
15. Bhandare, N., Antonelli, P.J., Morris, C.G., Malayapa, R.S. & Mendenhall, W.M. Ototoxicity after radiotherapy for head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 67, 469-479 (2007). (Pubitemid 46108326)
16. Chang, K.W. & Chinosornvatana, N. Practical grading system for evaluating cisplatin ototoxicity in children. J. Clin. Oncol. 28, 1788-1795 (2010).
17. Pan, C.C., Eisbruch, A., Lee, J.S., Snorrason, R.M., Ten Haken, R.K. & Kileny, P.R. Prospective study of inner ear radiation dose and hearing loss in head-andneck cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 61, 1393-1402 (2005). (Pubitemid 40470420)
18. Veenstra, D.L., Harris, J., Gibson, R.L., Rosenfeld, M., Burke, W. & Watts, C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet. Med. 9, 695-704 (2007). (Pubitemid 350287155)
19. Waguespack, J.R. & Ricci, A.J. Aminoglycoside ototoxicity: permeant drugs cause permanent hair cell loss. J. Physiol. (Lond.) 567, 359-360 (2005). (Pubitemid 41301035)
20. Lugassy, G. & Shapira, A. Sensorineural hearing loss associated with vincristine treatment. Blut 61, 320-321 (1990).
21. Aydogdu, I., Ozturan, O., Kuku, I., Kaya, E., Sevinc, A. & Yildiz, R. Bilateral transient hearing loss associated with vincristine therapy: case report. J. Chemother. 12, 530-532 (2000). (Pubitemid 32048172)
22. Lugassy, G. & Shapira, A. A prospective cohort study of the effect of vincristine on audition. Anticancer. Drugs 7, 525-526 (1996). (Pubitemid 26276341)
23. Riga, M. et al. The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions. Int. J. Pediatr. Otorhinolaryngol. 70, 1003-1008 (2006).
24. Wang, L., McLeod, H.L. & Weinshilboum, R.M. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
25. Oldenburg, J., Kraggerud, S.M., Brydøy, M., Cvancarova, M., Lothe, R.A. & Fossa, S.D. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and-M1, a retrospective cross sectional study. J. Transl. Med. 5, 70 (2007).
26. Riedemann, L. et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 8, 23-28 (2008).
27. Hirschhorn, J.N. & Altshuler, D. Once and again-issues surrounding replication in genetic association studies. J. Clin. Endocrinol. Metab. 87, 4438-4441 (2002). (Pubitemid 35247020)
28. Ross, C.J. et al. Corrigendum: genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 45, 578 (2013).
29. Visscher, H. et al. Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics J. 9, 362-372 (2009).
30. Weinshilboum, R.M. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell. Mol. Neurobiol. 26, 539-561 (2006).
31. Weinshilboum, R.M. & Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980). (Pubitemid 10061685)
32. Ochoa, B., Bobadilla, N., Arrellín, G. & Herrera, L.A. S-Adenosyl-L-methionine increases serum BUN and creatinine in cisplatin-treated mice. Arch. Med. Res. 40, 54-58 (2009).
33. Ballatori, N., Hammond, C.L., Cunningham, J.B., Krance, S.M. & Marchan, R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 204, 238-255 (2005). (Pubitemid 40545229)
34. Lee, Y.M. et al. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14, 213-223 (2004).
35. Yang, P., Ebbert, J.O., Sun, Z. & Weinshilboum, R.M. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J. Clin. Oncol. 24, 1761-1769 (2006). (Pubitemid 46622148)
36. Leitner, H.M., Kachadourian, R. & Day, B.J. Harnessing drug resistance: using ABC transporter proteins to target cancer cells. Biochem. Pharmacol. 74, 1677-1685 (2007). (Pubitemid 350088674)
37. Schrenk, D., Baus, P.R., Ermel, N., Klein, C., Vorderstemann, B. & Kauffmann, H.M. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol. Lett. 120, 51-57 (2001). (Pubitemid 32375070)
38. Young, L.C., Campling, B.G., Cole, S.P., Deeley, R.G. & Gerlach, J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 7, 1798-1804 (2001). (Pubitemid 32708651)
39. Young, L.C., Campling, B.G., Voskoglou-Nomikos, T., Cole, S.P., Deeley, R.G. & Gerlach, J.H. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 5, 673-680 (1999). (Pubitemid 29131979)
40. Oguri, T., Isobe, T., Fujitaka, K., Ishikawa, N. & Kohno, N. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int. J. Cancer 93, 584-589 (2001). (Pubitemid 32701419)
41. Chanock, S.J. et al. Replicating genotype-phenotype associations. Nature 447, 655-660 (2007). (Pubitemid 46889722)
42. Ioannidis, J.P., Ntzani, E.E., Trikalinos, T.A. & Contopoulos-Ioannidis, D.G. Replication validity of genetic association studies. Nat. Genet. 29, 306-309 (2001). (Pubitemid 33096456)
43. Blair, J.C., Peterson, M.E. & Viehweg, S.H. The effects of mild sensorineural hearing loss on academic performance of young school age children. Volta Rev. 87, 87-93 (2001).
44. Bess, F.H., Dodd-Murphy, J. & Parker, R.A. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 19, 339-354 (1998). (Pubitemid 28465218)
45. Qaddoumi, I. et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J. Clin. Oncol. 30, 1034-1041 (2012).
46. Orgel, E. et al. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr. Blood Cancer 58, 953-958 (2012).
47. Muldoon, L.L. et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Cancer Res. 6, 309-315 (2000). (Pubitemid 30065007)
48. Ross, C.J., Carleton, B., Warn, D.G., Stenton, S.B., Rassekh, S.R. & Hayden, M.R. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Ann. N. Y. Acad. Sci. 1110, 177-192 (2007). (Pubitemid 350043007)
49. Cancer Therapy Evalution Program-Common Terminology Criteria for Adverse Events-Version 3 http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf (2003).
50. Guo, S.W. & Thompson, E.A. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48, 361-372 (1992).
51. Afzal, S. et al. Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. J. Neurooncol. 97, 393-399 (2010).
52. DeLong, E.R., DeLong, D.M. & Clarke-Pearson, D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845 (1988).
53. Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).